Expanded Leadership Positions Seek to Bolster Progress in Hematology and Oncology Sectors
Golisano Children's Hospital has announced two significant appointments within its Division of Pediatric Hematology/Oncology. Dr. Jamie Flerlage and Dr. Jeffrey Andolina will take on key roles, aiming to advance the hospital's growing reputation in the field of pediatric cancer.
Dr. Jamie Flerlage, a renowned expert in pediatric Hodgkin's lymphoma, has been appointed as the division chief and academic director. She brings a wealth of experience to her new position, having worked at St. Jude Children's Research Hospital, where she trained in pediatric hematology/oncology and became a faculty member. Dr. Flerlage is nationally and internationally recognized for her expertise in this area, having been a speaker or participant at the 6th International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (ISCAYAHL) in 2025.
In her new roles, Dr. Flerlage will work to expand external and collaborative clinical research opportunities in Rochester and beyond. She will also serve as an assistant director of Clinical Research within Wilmot Cancer Institute's Clinical Trials Office (CTO). Her research focuses on novel therapies for patients with Hodgkin's lymphoma and identifying genome sequences related to hematopoietic malignancy.
Dr. Jeffrey Andolina, an expert in the treatment and care of children with leukemia and lymphoma, as well as children with other cancers and blood diseases, has been appointed as the clinical director of Pediatric Hematology and Oncology and associate chair for Pediatric Program Development. In his leadership role, Dr. Andolina will direct inpatient and outpatient clinical services for the division, lead clinical program development, and promote a unified approach to the medical care of pediatric hematology/oncology patients. His research interests include improving bone-marrow transplantation outcomes for children and young adults and evaluating reduced-intensity conditioning regimens for pediatric patients with malignant and non-malignant diseases, especially sickle cell anemia.
Jonathan W. Friedberg, MD, MMSc, director of Wilmot Cancer Institute, expressed excitement about Dr. Flerlage's appointment, stating that she will be a tremendous asset for their clinical research efforts, particularly for childhood cancers. Dr. Jill Halterman, interim chair of the Department of Pediatrics, expressed optimism about the leadership of Drs. Andolina and Flerlage, stating that they will help continue progress in the clinical mission and develop advanced treatments to serve children in New York State and beyond. Both Dr. Andolina and Dr. Flerlage will work to advance GCH's growing reputation in the field of pediatric cancer.
The Division of Pediatric Hematology/Oncology at Golisano Children's Hospital was nationally ranked in 2023 by U.S. News & World Report. With the addition of these two esteemed professionals, the division is poised to make even greater strides in the fight against childhood cancer. Dr. Flerlage will begin her new roles on October 1.
[1] For more precise information about Dr. Flerlage's research topics, I recommend consulting her professional or institutional profile, scientific publications, or conference abstracts in pediatric oncology.
- These new appointments aim to advance Golisano Children's Hospital's growing reputation, particularly in the field of pediatric cancer.
- The hospital's Division of Pediatric Hematology/Oncology, ranked nationally in 2023, is poised to make greater strides in the fight against childhood cancer.
- Science and medical research will be at the forefront of Dr. Jamie Flerlage's roles, with a focus on expanding external research opportunities for pediatric cancer.
- The finance and business sectors may also be impacted, as these appointments could lead to new opportunities for health-and-wellness companies, supporting research and development in medical-conditions like pediatric cancers.
